Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1966 1
1967 1
1968 4
1972 1
1973 1
1974 3
1975 2
1976 2
1977 1
1979 4
1980 2
1981 2
1982 4
1983 4
1984 3
1985 3
1986 3
1987 4
1988 3
1989 9
1990 2
1991 6
1992 7
1993 10
1994 5
1995 8
1996 14
1997 10
1998 9
1999 20
2000 14
2001 17
2002 12
2003 19
2004 21
2005 21
2006 30
2007 22
2008 49
2009 32
2010 41
2011 55
2012 47
2013 58
2014 57
2015 66
2016 72
2017 62
2018 48
2019 56
2020 67
2021 54
2022 30
2023 23
2024 14

Text availability

Article attribute

Article type

Publication date

Search Results

1,002 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Adult brain stem neoplasm"
Page 1
Cancer Stem Cells: Significance in Origin, Pathogenesis and Treatment of Glioblastoma.
Biserova K, Jakovlevs A, Uljanovs R, Strumfa I. Biserova K, et al. Cells. 2021 Mar 11;10(3):621. doi: 10.3390/cells10030621. Cells. 2021. PMID: 33799798 Free PMC article. Review.
Extensive research has been devoted to the role of CSCs in glioblastoma multiforme (GBM), the most common primary brain tumor in adults, which is characterized by a dismal prognosis because of its aggressive course and poor response to treatment. ...The six regulato …
Extensive research has been devoted to the role of CSCs in glioblastoma multiforme (GBM), the most common primary brain tumor in a …
Tumor Development and Angiogenesis in Adult Brain Tumor: Glioblastoma.
Ahir BK, Engelhard HH, Lakka SS. Ahir BK, et al. Mol Neurobiol. 2020 May;57(5):2461-2478. doi: 10.1007/s12035-020-01892-8. Epub 2020 Mar 9. Mol Neurobiol. 2020. PMID: 32152825 Free PMC article. Review.
Here, in this review, we highlight and summarize the various molecular mediators that regulate GBM angiogenesis with focus on recent clinical research on the potential of exploiting angiogenic pathways as a strategy in the treatment of GBM patients....
Here, in this review, we highlight and summarize the various molecular mediators that regulate GBM angiogenesis with focus on recent clin …
How I treat secondary CNS involvement by aggressive lymphomas.
Alderuccio JP, Nayak L, Cwynarski K. Alderuccio JP, et al. Blood. 2023 Nov 23;142(21):1771-1783. doi: 10.1182/blood.2023020168. Blood. 2023. PMID: 37702537
The incidence, timing in disease course, location, evidence supporting the use of CNS prophylaxis, and treatment pathways vary according to histology. No randomized data exist to delineate the best treatment approaches with current recommendations based on retrospective an …
The incidence, timing in disease course, location, evidence supporting the use of CNS prophylaxis, and treatment pathways vary according to …
R-MPV followed by high-dose chemotherapy with TBC and autologous stem-cell transplant for newly diagnosed primary CNS lymphoma.
Omuro A, Correa DD, DeAngelis LM, Moskowitz CH, Matasar MJ, Kaley TJ, Gavrilovic IT, Nolan C, Pentsova E, Grommes CC, Panageas KS, Baser RE, Faivre G, Abrey LE, Sauter CS. Omuro A, et al. Blood. 2015 Feb 26;125(9):1403-10. doi: 10.1182/blood-2014-10-604561. Epub 2015 Jan 7. Blood. 2015. PMID: 25568347 Free PMC article. Clinical Trial.
High-dose methotrexate-based chemotherapy is the mainstay of treatment of primary central nervous system lymphoma (PCNSL), but relapses remain frequent. High-dose chemotherapy (HDC) with autologous stem-cell transplant (ASCT) may provide an alternative to address chemoresi …
High-dose methotrexate-based chemotherapy is the mainstay of treatment of primary central nervous system lymphoma (PCNSL), but relapses rema …
Neural stem cell delivery of an oncolytic adenovirus in newly diagnosed malignant glioma: a first-in-human, phase 1, dose-escalation trial.
Fares J, Ahmed AU, Ulasov IV, Sonabend AM, Miska J, Lee-Chang C, Balyasnikova IV, Chandler JP, Portnow J, Tate MC, Kumthekar P, Lukas RV, Grimm SA, Adams AK, Hébert CD, Strong TV, Amidei C, Arrieta VA, Zannikou M, Horbinski C, Zhang H, Burdett KB, Curiel DT, Sachdev S, Aboody KS, Stupp R, Lesniak MS. Fares J, et al. Lancet Oncol. 2021 Aug;22(8):1103-1114. doi: 10.1016/S1470-2045(21)00245-X. Epub 2021 Jun 29. Lancet Oncol. 2021. PMID: 34214495 Free PMC article. Clinical Trial.
Recruitment is complete and the trial is finished. The trial is registered with ClinicalTrials.gov, NCT03072134. ...Our immunological and histopathological findings support continued investigation of NSC-CRAd-S-pk7 in a phase 2/3 clinical trial. FUNDIN …
Recruitment is complete and the trial is finished. The trial is registered with ClinicalTrials.gov, NCT03072134. ...Our immuno …
TRAF4 Maintains Deubiquitination of Caveolin-1 to Drive Glioblastoma Stemness and Temozolomide Resistance.
Li Y, Wang T, Wan Q, Wang Q, Chen Z, Gao Y, Ye Y, Lin J, Zhao B, Wang H, Yang J, Zhao K, Lu N. Li Y, et al. Cancer Res. 2022 Oct 4;82(19):3573-3587. doi: 10.1158/0008-5472.CAN-21-3882. Cancer Res. 2022. PMID: 35895752
Glioblastoma (GBM) is the most common type of primary adult brain tumor. Glioma stem cell (GSC) residence and temozolomide (TMZ) resistance in GBM both contribute to poor patient outcome. ...Here, we report that TRAF4 is preferentially overexpressed in GSCs a …
Glioblastoma (GBM) is the most common type of primary adult brain tumor. Glioma stem cell (GSC) residence and temozolom …
Lymphoblastic lymphoma.
Cortelazzo S, Ferreri A, Hoelzer D, Ponzoni M. Cortelazzo S, et al. Crit Rev Oncol Hematol. 2017 May;113:304-317. doi: 10.1016/j.critrevonc.2017.03.020. Epub 2017 Mar 18. Crit Rev Oncol Hematol. 2017. PMID: 28427520 Review.
Lymphoblastic lymphoma (LBL) is a neoplasm of immature B cells committed to the B-(B-LBL) or T-cell lineage (T-LBL) that accounts for approximately 2% of all lymphomas. ...LBL occurs more commonly in children than in adults, mostly in males. A bone marrow involvemen …
Lymphoblastic lymphoma (LBL) is a neoplasm of immature B cells committed to the B-(B-LBL) or T-cell lineage (T-LBL) that accounts for …
Primary Central Nervous System Lymphomas.
Chukwueke U, Grommes C, Nayak L. Chukwueke U, et al. Hematol Oncol Clin North Am. 2022 Feb;36(1):147-159. doi: 10.1016/j.hoc.2021.09.004. Hematol Oncol Clin North Am. 2022. PMID: 34801161 Review.
Primary central nervous system lymphoma is a rare and aggressive extranodal non-Hodgkin lymphoma restricted to the brain, spinal cord, cerebrospinal fluid, and eyes. Optimization of treatment including high-dose methotrexate-based chemotherapy followed by consolidation the …
Primary central nervous system lymphoma is a rare and aggressive extranodal non-Hodgkin lymphoma restricted to the brain, spinal cord …
ATRX/EZH2 complex epigenetically regulates FADD/PARP1 axis, contributing to TMZ resistance in glioma.
Han B, Meng X, Wu P, Li Z, Li S, Zhang Y, Zha C, Ye Q, Jiang C, Cai J, Jiang T. Han B, et al. Theranostics. 2020 Feb 10;10(7):3351-3365. doi: 10.7150/thno.41219. eCollection 2020. Theranostics. 2020. PMID: 32194873 Free PMC article.
Rationale: Glioma is the most common primary malignant brain tumor in adults. Chemoresistance of temozolomide (TMZ), the first-line chemotherapeutic agent, is a major issue in the management of patients with glioma. ...
Rationale: Glioma is the most common primary malignant brain tumor in adults. Chemoresistance of temozolomide (TMZ), the first …
Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International Extranodal Lymphoma Study Group-32 phase 2 trial.
Ferreri AJM, Cwynarski K, Pulczynski E, Fox CP, Schorb E, La Rosée P, Binder M, Fabbri A, Torri V, Minacapelli E, Falautano M, Ilariucci F, Ambrosetti A, Roth A, Hemmaway C, Johnson P, Linton KM, Pukrop T, Sønderskov Gørløv J, Balzarotti M, Hess G, Keller U, Stilgenbauer S, Panse J, Tucci A, Orsucci L, Pisani F, Levis A, Krause SW, Schmoll HJ, Hertenstein B, Rummel M, Smith J, Pfreundschuh M, Cabras G, Angrilli F, Ponzoni M, Deckert M, Politi LS, Finke J, Reni M, Cavalli F, Zucca E, Illerhaus G; International Extranodal Lymphoma Study Group (IELSG). Ferreri AJM, et al. Lancet Haematol. 2017 Nov;4(11):e510-e523. doi: 10.1016/S2352-3026(17)30174-6. Epub 2017 Oct 17. Lancet Haematol. 2017. PMID: 29054815 Clinical Trial.
BACKGROUND: The International Extranodal Lymphoma Study Group-32 (IELSG32) trial is an international randomised phase 2 study that addresses two key clinical questions in the treatment of patients with newly diagnosed primary CNS lymphoma. ...Here, we report …
BACKGROUND: The International Extranodal Lymphoma Study Group-32 (IELSG32) trial is an international randomised phase 2 study …
1,002 results